---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-014464"
form_type: "8-K"
ticker: "VTAK"
cik: "0001716621"
company_name: "Catheter Precision, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:31:27.411438+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catheter Precision posts Q3 net loss $4.1M, revenue $96K; warrants raise $4.9M

## Summary
- Sales revenue for Q3 2024 was ~$96K, net loss $4.1M (including $1.7M non-cash charges); nine-month net loss $11.0M.
- Cash at Sept 30 was $1.3M; on Oct 25, 2024, warrant exercise raised gross proceeds of $4.9M.
- Company has 87 hospitals in pipeline; 32 institutions in ongoing evaluations; CE Mark for LockeT expected by end of Q1 2025.
- Commercial team includes new CCO Marie-Claude Jaques; VIVO procedures ongoing in multiple European countries.
- Over 130 patients enrolled in LockeT II comparative study; initial LockeT study published in JCE in August.

## SEC filing metadata
- accession: 0001654954-24-014464
- form_type: 8-K
- ticker: VTAK
- cik: 0001716621
- company_name: Catheter Precision, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000165495424014464/0001654954-24-014464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000165495424014464/catheter_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-014464
- JSON: https://secwatch.observer/filing/0001654954-24-014464.json
- Plain text: https://secwatch.observer/filing/0001654954-24-014464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.